Spark Biomedical Awarded $1.15M Department of Defense Phase II STTR Grant in Partnership with Battelle Memorial Institute
Retrieved on:
星期二, 八月 29, 2023
Sparrowhawk, Partnership, Headache, Firefighter, Tan, Anxiety, Health care, Sparrow, Quality of life, Woman, First responder, Opioid, Post-traumatic stress disorder, Battelle, Patient, NIDA, Nausea, Emergency department, Injury, FDA, ASR, Mental health, Irritability, PTSD, Substance abuse, Pharmaceutical industry, Nursing, Medical device
In partnership with Battelle, Sparrow Hawk development brings a rapidly deployable, non-invasive, wearable approach to ASR prevention and treatment into the battlefield setting.
Key Points:
- In partnership with Battelle, Sparrow Hawk development brings a rapidly deployable, non-invasive, wearable approach to ASR prevention and treatment into the battlefield setting.
- ASR can result in anxiety, nausea, irritability, dysregulated emotions, poor sleep, poor concentration, cognitive fatigue, and headaches.
- During Phase I, the team at Spark Biomedical successfully completed critical benchmarks by developing performance parameters and form factors for a revolutionary compact, disposable, cable-free, “all-in-one” wearable tAN device.
- In Phase II Spark Biomedical and Battelle will focus on:
Testing the device in a clinical setting to evaluate its efficacy in restoring performance on operationally relevant tasks within a meticulously crafted clinical model of laboratory stress.